![]() |
市場調査レポート
商品コード
1541181
軟部組織修復市場レポート:製品、用途、最終用途、地域別、2024年~2032年Soft Tissue Repair Market Report by Product, Application, End Use, and Region 2024-2032 |
||||||
カスタマイズ可能
|
軟部組織修復市場レポート:製品、用途、最終用途、地域別、2024年~2032年 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2~3営業日
|
世界の軟部組織修復市場規模は2023年に140億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに197億米ドルに達し、2024年から2032年の間に3.8%の成長率(CAGR)を示すと予測しています。
軟部組織は、筋肉、腱、筋膜、神経、脂肪、靭帯、血管、滑膜で構成され、身体の他の構造や器官を連結し、取り囲み、支えています。多くの身体活動がこれらの損傷を引き起こし、その結果、痛み、捻挫、緊張、腫れ、滑液包炎、腱炎、打撲傷などが生じる。その結果、軟部組織の回復、修復、再生のために、さまざまな治療介入が利用されます。例えば、キトサン、ゼラチン、アルギン酸のような天然ポリマーを使った足場が、その修復のための生体材料として使われています。このほか、同種移植片や異種移植片の使用も、世界中で深刻な損傷の修復に利用されつつあります。
個人、特に子供たちのプロスポーツへの参加の増加により、軟部組織の損傷のリスクが高まっています。このことは、子供の身体的健康に対する親の関心の高まりと相まって、市場成長にプラスの影響を与える主な要因の一つとなっています。その修復は、より早い回復と運動能力の向上に役立ちます。これとは別に、高齢化人口の増加が、高い効率性を持ち、損傷した軟部組織を短時間で効果的に修復できるバイオマテリアルの需要を喚起しています。これらの生体材料は、硬膜断裂、胸壁再建、心臓・循環器外科手術、腹壁修復、骨盤臓器脱治療など、さまざまな軟部組織手術にも使用されています。さらに、筋骨格系障害の増加により、骨とそれに関連する軟部組織を再編成するための生物医学的インプラントの必要性が高まっています。有利な償還政策、医療ツーリズムの人気の高まり、研究開発(R&D)活動への投資の増加など、その他の要因も市場の成長を強化すると予想されます。
The global soft tissue repair market size reached US$ 14.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 19.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032.
Soft tissues comprise muscles, tendons, fascia, nerves, fat, ligaments, blood vessels, and synovial membranes that connect, surround, and support other structures and organs of the body. Many physical activities can lead to their damage, which further results in pain, sprains, strains, swelling, bursitis, tendinitis, and contusions. As a result, various remedial interventions are utilized for restoring, repairing, and regenerating soft tissues. For instance, scaffolds made using natural polymers like chitosan, gelatin, and alginate are used as biomaterials for their repair. Besides this, the use of allografts and xenografts is also gaining traction for repairing severe damages around the world.
The growing participation of individuals, especially children, in professional sports increases the risk of developing an injury in soft tissues. This, in confluence with the increasing concerns among parents about the physical health of their child, represents one of the primary factors influencing the market growth positively. Its repair helps in faster recovery and improving athletic performance. Apart from this, the growing aging population is catalyzing the demand for biomaterials that have high efficiency and can effectively repair damaged soft tissues in a short time. These biomaterials are also used in a variety of soft tissue procedures, including dural tears, chest wall reconstruction, cardiac and cardiovascular surgery, abdominal wall repair, and pelvic organ prolapse treatment. Furthermore, rising incidences of musculoskeletal disorders is promoting the need for biomedical implants to reorganize the bone and its associated soft tissues. Other factors, such as favorable reimbursement policies, the increasing popularity of medical tourism, and rising investments in research and development (R&D) activities, are anticipated to strengthen the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global soft tissue repair market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end use.
Fixation Products
Suture
Suture Anchors
Tissue Patch/Match
Biological
Synthetic
Orthopedic Surgery
Breast Reconstruction
Hernia Repair
Skin Repair
Vaginal Sling Repair
Cardiovascular Surgery
Others
Hospitals and Clinics
Research and Academic Institutes
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Arthrex Inc., Becton Dickinson and Company, Baxter International Inc., Cryolife Inc., Integra LifeSciences Corporation, Johnson & Johnson, Medtronic Plc, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation and Terumo Corporation.